Related Experiment Video
Updated: Apr 21, 2026

A Recovery Cardiopulmonary Bypass Model Without Transfusion or Inotropic Agents in Rats
Published on: March 23, 2018
Vasopressin aggravates cardiopulmonary bypass-induced gastric mucosal ischemia
Hagen Bomberg1, Benjamin Bierbach, Stephan Flache
1Department of Thoracic and Cardiovascular Surgery, University Hospital of Saarland, Homburg/Saar, Germany.
Insights
Vasopressin worsens gastric microvascular perfusion during cardiopulmonary bypass (CPB) but prevents endothelin system changes and gastric injury. This suggests vasopressin
Area of Science:
- Cardiovascular Surgery
- Gastroenterology
- Critical Care Medicine
Background:
- Upper gastrointestinal bleeding (UGIB) is a common complication post-cardiac surgery with cardiopulmonary bypass (CPB).
- Endothelin system activation and microcirculatory dysfunction are implicated in UGIB pathogenesis.
- The role of vasopressin in modulating these factors during CPB requires elucidation.
Purpose of the Study:
- To investigate the impact of vasopressin on gastric mucosal microcirculation during CPB.
- To determine the involvement of the endothelin system in vasopressin's effects on gastric mucosa.
- To assess vasopressin's influence on gastric mucosal injury markers.
Main Methods:
- Pigs underwent 1-hour CPB, with one group receiving vasopressin to maintain arterial pressure.
- Gastric mucosal blood flow, oxygen saturation, and systemic hemodynamics were continuously monitored.
- Gastric mucosal endothelin-1 (ET-1) and receptor expressions (ET(A), ET(B)), injury, apoptosis, and leukocytic infiltration were analyzed.
Main Results:
- CPB impaired gastric microvascular perfusion and increased ET-1 and ET(A) expression.
- Vasopressin exacerbated CPB-associated malperfusion but fully prevented ET-1 and ET(A) upregulation.
- Vasopressin did not induce significant gastric mucosal injury, apoptosis, or leukocytic infiltration.
Conclusions:
- Vasopressin worsens CPB-induced microvascular malperfusion in the gastric mucosa.
- Despite aggravating malperfusion, vasopressin effectively mitigates endothelin system activation.
- Vasopressin administration during CPB does not lead to gastric mucosal injury.
Background/Aim:
Upper gastrointestinal bleeding (UGIB) is one of the most frequent gastrointestinal complications after cardiac surgery with cardiopulmonary bypass (CPB). Endothelin expression and microcirculatory dysfunction have been shown to be involved in UGIB. The aim of this study was to analyze the effect of vasopressin during CPB on the gastric mucosal microcirculation and the involvement of the endothelin system.
Methods:
Eighteen pigs were randomized into three groups (n = 6 each): group I = sham, group II = CPB (1-hour CPB) and group III = CPB + vasopressin (1-hour CPB and vasopressin administration during CPB to maintain baseline arterial pressure). All animals were observed for a further 90 min after termination of CPB. Systemic hemodynamics as well as blood flow and oxygen saturation of the gastric mucosa were measured continuously. At the end of the experiment, the gastric mucosal expressions of endothelin-1 (ET-1) and its receptor subtypes A (ET(A)) and B (ET(B)) were determined by polymerase chain reaction. Gastric mucosal injury, apoptotic cell death and leukocytic infiltration were determined by histology and immunohistochemical analyses of cleaved caspase-3 and myeloperoxidase.
Results:
CPB decreased gastric microvascular perfusion, which was associated with an increased expression of ET-1 and ET(A). Vasopressin aggravated the CPB-associated malperfusion, whereas it completely abrogated the upregulation of ET-1 and ET(A). Interestingly, vasopressin did not induce gastric mucosal morphologic injury, leukocytic infiltration or apoptotic cell death.
Conclusion:
Vasopressin aggravates CPB-associated microvascular malperfusion of the gastric mucosa but does not induce gastric mucosal injury.
Related Concept Videos
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inotropic Agents
Cardiopulmonary Resuscitation IV: Pharmacological Management

